OKYO Pharma Ltd ADR - Asset Resilience Ratio

Latest as of March 2023: 84.69%

OKYO Pharma Ltd ADR (OKYO) has an Asset Resilience Ratio of 84.69% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$4.41 Million

Cash + Short-term Investments

Total Assets

$5.20 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2017)

This chart shows how OKYO Pharma Ltd ADR's Asset Resilience Ratio has changed over time. Check asset allocation strategy of OKYO Pharma Ltd ADR to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down OKYO Pharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OKYO Pharma Ltd ADR market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$4.41 Million	84.69%
Total Liquid Assets	$4.41 Million	84.69%

Asset Resilience Insights

Very High Liquidity: OKYO Pharma Ltd ADR maintains exceptional liquid asset reserves at 84.69% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

OKYO Pharma Ltd ADR Industry Peers by Asset Resilience Ratio

Compare OKYO Pharma Ltd ADR's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
ALTEOGEN Inc KQ:196170	Biotechnology	55.57%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	34.94%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Inventiva S.A PA:IVA	Biotechnology	52.73%

Annual Asset Resilience Ratio for OKYO Pharma Ltd ADR (2009–2017)

The table below shows the annual Asset Resilience Ratio data for OKYO Pharma Ltd ADR.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2017-03-31	60.74%	$16.86 Million	$27.76 Million	+9.96pp
2010-03-31	50.77%	$27.49 Million	$54.13 Million	-15.22pp
2009-03-31	65.99%	$25.25 Million	$38.27 Million	--

pp = percentage points

About OKYO Pharma Ltd ADR

NASDAQ:OKYO USA Biotechnology

Market Cap

$59.80 Million

Market Cap Rank

#21141 Global

#4693 in USA

Share Price

$1.59

Change (1 day)

-1.85%

52-Week Range

$1.34 - $3.27

All Time High

$3.74